Protocols
ARCELLX-ACLX-001-DDBCMA Phase I OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-term Safety Follow-up
ARCELLX-ARC-112A-CART-DDBCMA Phase II OPEN TO ACCRUAL
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CARSGEN-CT053-MM-02 Phase I/II OPEN TO ACCRUAL
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
CELGENE-GC-LTFU-001 Phase N/A OPEN TO ACCRUAL
Long-Term Follow-up Protocol for Subjects treated with Gene-Modified T Cells
FATE-FT576-101-MM Phase I OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
JNJ-68284528MMY2005-OOS Phase II OPEN TO ACCRUAL *
A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with MM
JNJ-MY4002-CARTINUE-LTFU Phase N/A OPEN TO ACCRUAL
Long-term Follow-up Study of Participants Previously Treated with Ciltacabtagene Autoleucel
NOVARTIS-ADPT07A12101BCMA-CART Phase I OPEN TO ACCRUAL
Phase I, Open Label Study of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients with Relapsed and/or Refractory Multiple Myeloma